Patients who were drug-nave ( HbA@c @ % and @ % ) , or on background glucose-lowering therapy ( HbA@c @ % and @ % ) , and were at high risk of CV events , were randomized ( @:@:@ ) and treated with empagliflozin @ mg , empagliflozin @ mg , or placebo ( double blind , double dummy ) superimposed upon the standard of care .